XON Intrexon Corporation

5.96
-0.01  -0%
Previous Close 5.97
Open 6.09
Price To Book 3.46
Market Cap 965,940,830
Shares 162,070,609
Volume 1,061,352
Short Ratio
Av. Daily Volume 1,002,045
Stock charts supplied by TradingView

NewsSee all news

  1. Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting

    GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ:XON), yesterday presented preliminary

  2. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  3. Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

    GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ:XON), today announced the completion of

  4. Intrexon to Announce Third Quarter Financial Results on November 12th

    GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it

  5. Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics"), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 dosing has been completed - noted November 7, 2019.
INXN-4001
Heart failure
Phase 1/1b initiation announced June 26, 2019.
PRGN-3006
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1b/2a data due in 2020.
AG019
Type 1 diabetes
Phase 1 initiation of dosing announced August 5, 2019.
PRGN-3005
Ovarian cancer

Latest News

  1. Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting

    GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ:XON), yesterday presented preliminary

  2. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  3. Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

    GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ:XON), today announced the completion of

  4. Intrexon to Announce Third Quarter Financial Results on November 12th

    GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it

  5. Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics"), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2,

  6. Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of

  7. Next Green Wave Achieves Operational Milestones For Intrexon's Botticelli(TM) Cannabis Plantlet Production

    NGW Nursery Capacity Established and Second Harvest CompletedVancouver, British Columbia--(Newsfile Corp. - September 24, 2019) - Next Green Wave Holdings Inc. (CSE:NGW) (OTCQX:NXGWF) ("Next Green Wave", "NGW" or the

  8. Next Green Wave Achieves Operational Milestones For Intrexon's Botticelli™ Cannabis Plantlet Production

    VANCOUVER, British Columbia, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX:NXGWF) ("Next Green Wave", "NGW" or the "Company") announces that it has completed the

  9. Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer

    OCEANSIDE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the recruitment of Feng Lin, MD, Ph.D., as Chief Scientific